16d agoSeeking AlphaBEARISH 34General
Chemed drops amid report on Vista Healthcare business
Chemed (CHE) drops 4.6% after Capitol Forum report on Vista Healthcare; activist Barington urges review and board changes.
Archived explainer. For the current picture see today's CHE page.
Why Is CHEMED CORP NEW (CHE) Stock Down Today?
By the Top Tier Newswire AI Desk · August 27, 2026 at 3:07 PM ET · reviewed against 1 wire stories
CHEMED CORP NEW (CHE) is down -5.38% in the latest session. Our newswire has captured 1 story on CHE across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 34/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Chemed Corp (CHE) fell 5.38% to $519.05 in afternoon trading on August 27, 2026, marking a sharp decline driven by a Capitol Forum report alleging mismanagement at its Vista Healthcare subsidiary. The report, which surfaced on social media, claims that Vista Healthcare misdiagnosed dementia patients and manipulated evaluation scores to qualify them for hospice care. The allegations have sparked calls for a federal investigation and board-level changes from activist investor Barington. The stock opened with a modest 0.5% gap down but quickly deteriorated, hitting a session low of $501.84 before stabilizing slightly in the final hours.
What Happened
The Capitol Forum’s report, which was shared on X, detailed internal documents reviewed by an expert who called for federal scrutiny. Seeking Alpha reported that the stock dropped 4.6% following the allegations. Chemed’s CEO and President, Kevin J. McNamara, and Executive Vice President Spencer S. Lee sold shares on August 3 and August 21, adding to investor unease. Despite recent positive earnings and guidance upgrades, the stock has struggled with the reputational and operational concerns raised by the report.
What The Data Shows
The stock’s intraday session showed a sharp decline after a modest opening gap down, with volume at 0.2 million shares, matching the 3-month average. The 52-week tape recorded eight fresh 52-week lows on August 27. Chemed’s fundamentals remain strong, with a P/E of 27.6, a 10.6% net margin, and a 3.3% revenue growth rate. However, the recent insider sales and the Capitol Forum report have overshadowed these metrics. The stock is now trading near the lower end of its 52-week range, at $519.05.
What To Watch
Chemed’s next earnings report is not scheduled for several months, but investors will closely monitor coverage breadth and any additional developments regarding the Capitol Forum’s allegations. The stock’s recent guidance and analyst ratings remain positive, but sentiment has deteriorated significantly in the past week.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CHE by the numbers
Last: $519.05Session: -5.38%7 sessions: -1.73%Coverage: 1 stories / 1 sourcesAI sentiment: 34/100 (bearish)Mkt cap: $7.1BP/E: 27.652w: $365.20 to $557.00
The headlines behind the move
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CHE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CHE move explainers: 2026-08-28 · 2026-08-27